Clinical Trial

A Study to See How Safe a New Medicine (NNC0705-0001) is in Healthy People

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The study is testing a new study medicine (called NNC0705-0001), as a potential medicine to treat chronic systemic inflammation, which is known for increasing the risk of developing cardiometabolic diseases. The aim of this study is to see if the study medicine is safe, how it works in our body, and what our body does to the study medicine. The participant will either get NNC0705-0001 or placebo (a "dummy medicine" without the active ingredient). Which treatment the participant gets is decided by chance. The study consists of 3 parts: PART A - single ascending dose (SAD); PART B - multiple ascending doses (MAD) and PART C - food effect (FE) on the pharmacokinetic (PK) properties of NNC0705-0001 and will last about 35 days (PART A) and 41 days (PART B and C).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-06-11; most recent amendment 2026-03-10.
Status change: Recruiting → Completed 2026-01-30
Status change: Not Yet Recruiting → Recruiting 2025-08-10
Trial Details
NCT Number NCT07029568
Lead Sponsor Novo Nordisk A/S
Conditions Healthy Volunteers, Chronic Kidney Disease
Enrollment 116 participants
Start Date 2025-06-13
Primary Completion 2025-11-04 (estimated)
Study Completion 2025-12-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-11